Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Sponsor
University of California, San Francisco (Other)
Overall Status
Available
CT.gov ID
NCT00508963
Collaborator
(none)
1
Study Details
Study Description
Brief Summary
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Expanded Access
Official Title:
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- Biopsy proven new world cutaneous or mucocutaneous leishmania
Exclusion Criteria:
-
Prolonged QT
-
Liver disease
-
Pancreatitis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of CA at San Francisco Hospitals and Clinics | San Francisco | California | United States | 94143 |
Sponsors and Collaborators
- University of California, San Francisco
Investigators
- Principal Investigator: Brian Schwartz, MD, University of CA at San Francisco
- Principal Investigator: Kanade Shinkai, MD, University of CA at San Francisco
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00508963
Other Study ID Numbers:
- UCSF Infectious Diseases
First Posted:
Jul 30, 2007
Last Update Posted:
Mar 9, 2020
Last Verified:
Mar 1, 2020
Keywords provided by University of California, San Francisco
Additional relevant MeSH terms: